HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Stranded Biotech Asset Intelligence

Explore Opportunities

Find → Filter → Understand → Compare → Watch → Resolve. Discovery priority is not acquisition readiness.

1067 matching exact-name labels; not unique global drugs.

Select 2–10 for a subscription comparison.

UNKNOWN · LOW discovery confidence

V540A-2

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: strategic reprioritization. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for V540A-2 in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

V540A-3

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: strategic reprioritization. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for V540A-3 in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Vactosertib

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Vactosertib in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Vaginal Cream with Applicator

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Vaginal Cream with Applicator in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Valproic Acid

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Valproic Acid in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Valsartan

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Valsartan in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Valsartan 160mg (blinded)

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: financing failure. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Valsartan 160mg (blinded) in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Vancomycin

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Vancomycin in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

Vandetanib

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Vandetanib in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Vasopressor Therapy

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Vasopressor Therapy in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · UNKNOWN discovery confidence

Velcade®

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE ·
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Velcade® in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →

UNKNOWN · LOW discovery confidence

Vemurafenib (Zelboraf®)

Reported program or trial event; neither availability nor investment recommendation

Why this survived

Selected for further evidence review: inadequate public evidence. Discovery is not buyer qualification.

MODEL INFERENCE · Source 1
Human SignalUNKNOWN
Cheap TruthUNKNOWN
AcquirabilityUNKNOWN

UNKNOWN

Next Best Diligence Question

What primary evidence resolves human efficacy for Vemurafenib (Zelboraf®) in this exact treatment and indication context?

Why it matters and what could change

Human Signal: human efficacy is UNKNOWN; resolve this component before making a stronger decision.

Evidence needed: Source-bound, dated evidence for human efficacy, including contradictory findings and scope limitations.

Likely source: Official trial arm-level results, primary PubMed human studies and protocols

Continue diligence, deprioritize or retain UNKNOWN; no automatic promotion.

Fatal flaw: Unknown. No known fatal flaw is not asserted without complete scoped review.

Evidence completeness — coverage, not confidence

Human Signal: 0 / 5 gate components adjudicated

Cheap Truth: 0 / 6 gate components adjudicated

Clean Rights: 0 / 6 gate components adjudicated

Market Pull: 0 / 5 gate components adjudicated

Understand this lead →